Contraception News and Research

Latest Contraception News and Research

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Mylan N.V. today announced the U.S. launch of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott's Generess Fe Tablets.

7 Apr 2015

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy.

30 Mar 2015

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

10 Mar 2015

Researchers one step closer to unraveling complex processes crucial to sperm development

Researchers are one step closer to unraveling the extraordinarily complex series of processes that leads to an event crucial to human reproduction: the creation of sperm.

5 Mar 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Bayer expands patient assistance program for intrauterine devices

Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH (Access and Resources for Contraceptive Health) program will provide Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg and Mirena (levonorgestrel-releasing intrauterine system) 52 mg to low-income women who meet eligibility criteria.

23 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Catholics for Choice calls on Pope Francis to open childcare facilities in Vatican City

Today, in light of Pope Francis' comments that he believes "not having children is a selfish choice,"Catholics for Choice suggests that the pope, cardinals, bishops and priests that make up the citizens of Vatican City consider opening and running childcare facilities for the women in the world to give the hierarchy some hands-on experience.

12 Feb 2015

LA BioMed's Christina Wang receives Mayo H. Soley Award for outstanding research work

Christina Wang, MD, Los Angeles Biomedical Research Institute lead researcher, has received a top honor for her outstanding research work, the Mayo H. Soley Award, at the 2015 Western Regional Meetings of five top research societies in the West.

7 Feb 2015

Providing knowledge about contraception can significantly improve use of isotretinoin

Providing women who take a powerful acne drug with a fact sheet about contraception while visiting the dermatologist can significantly improve their awareness of the most effective birth control options and may prevent unintended pregnancies and birth defects that can be caused by the drug, according to a University of Pittsburgh School of Medicine study published Feb. 4 in the journal JAMA Dermatology.

5 Feb 2015

News study finds association between chronic fatigue syndrome and early menopause

A newfound link between chronic fatigue syndrome (CFS) and early menopause was reported online today in Menopause, the journal of The North American Menopause Society.

4 Feb 2015

Taking hormonal contraceptives for five years doubles brain tumour risk

Taking a hormonal contraceptive for at least five years is associated with a possible increase in a young woman's risk of developing a rare tumour, glioma of the brain. This project focussed on women aged 15 -49 years and the findings are published in the British Journal of Clinical Pharmacology.

22 Jan 2015

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.

16 Jan 2015

Injectable hormonal contraceptive appears to increase HIV risk in women

Women using depot medroxyprogesterone acetate (DMPA), commonly known as Depo-Provera or the birth control shot, have a moderately increased risk of becoming infected with HIV, a large meta-analysis of 12 studies involving more than 39 500 women published in The Lancet Infectious Diseases has found. Other forms of hormonal contraception, including oral contraceptive pills, do not appear to increase this risk.

12 Jan 2015

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis.

23 Dec 2014

Research outlines new model for measuring acceptability of contraceptive vaginal ring

The Population Council published new research in the November issue of the journal Contraception demonstrating that an investigational one-year contraceptive vaginal ring containing Nestorone and ethinyl estradiol was found to be highly acceptable among women enrolled in a Phase 3 clinical trial.

18 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

The University of Texas Medical Branch is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the National Institutes of Health to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million.

26 Nov 2014

Contraception News and Research

Latest Contraception News and Research

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Hospira announces availability of INFLECTRA (infliximab) in Canada

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

Researchers one step closer to unraveling complex processes crucial to sperm development

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Bayer expands patient assistance program for intrauterine devices

Actavis provides overview of standalone global pharmaceutical development pipeline

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Catholics for Choice calls on Pope Francis to open childcare facilities in Vatican City

LA BioMed's Christina Wang receives Mayo H. Soley Award for outstanding research work

Providing knowledge about contraception can significantly improve use of isotretinoin

News study finds association between chronic fatigue syndrome and early menopause

Taking hormonal contraceptives for five years doubles brain tumour risk

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

Injectable hormonal contraceptive appears to increase HIV risk in women

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Research outlines new model for measuring acceptability of contraceptive vaginal ring

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Contraception News and Research

Latest Contraception News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in